BioNTech SE Sponsored ADR (NASDAQ:BNTX) Sees Significant Decrease in Short Interest

BioNTech SE Sponsored ADR (NASDAQ:BNTX) saw a large decline in short interest in March. As of March 13th, there was short interest totaling 3,537,489 shares, a decline of 20.7% from the February 26th total of 4,462,537 shares. Approximately 1.8% of the company’s shares are sold short. Based on an average trading volume of 2,504,103 shares, the days-to-cover ratio is presently 1.4 days.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently added to or reduced their stakes in BNTX. Royal Bank of Canada increased its position in shares of BioNTech by 95.9% in the 1st quarter. Royal Bank of Canada now owns 7,177 shares of the company’s stock valued at $653,000 after purchasing an additional 3,514 shares during the last quarter. NewEdge Advisors LLC purchased a new stake in shares of BioNTech during the 1st quarter worth $167,000. Geode Capital Management LLC lifted its position in shares of BioNTech by 2.4% during the 2nd quarter. Geode Capital Management LLC now owns 103,750 shares of the company’s stock worth $11,046,000 after purchasing an additional 2,402 shares during the last quarter. Russell Investments Group Ltd. grew its stake in shares of BioNTech by 368,800.0% during the second quarter. Russell Investments Group Ltd. now owns 11,067 shares of the company’s stock worth $1,178,000 after purchasing an additional 11,064 shares in the last quarter. Finally, Virtus Investment Advisers LLC increased its holdings in BioNTech by 42.3% in the second quarter. Virtus Investment Advisers LLC now owns 4,236 shares of the company’s stock valued at $451,000 after buying an additional 1,260 shares during the last quarter. Institutional investors and hedge funds own 15.52% of the company’s stock.

BioNTech Stock Performance

Shares of BNTX opened at $85.68 on Monday. The stock has a 50-day simple moving average of $103.70 and a 200-day simple moving average of $101.60. The company has a debt-to-equity ratio of 0.01, a quick ratio of 7.49 and a current ratio of 7.54. The stock has a market capitalization of $20.56 billion, a PE ratio of -16.35 and a beta of 1.51. BioNTech has a 1 year low of $79.52 and a 1 year high of $124.00.

Analyst Ratings Changes

Several analysts have recently issued reports on BNTX shares. Leerink Partners cut shares of BioNTech from an “outperform” rating to a “market perform” rating and set a $113.00 price target on the stock. in a research report on Monday, February 2nd. Wall Street Zen cut shares of BioNTech from a “hold” rating to a “sell” rating in a report on Saturday, March 14th. Raymond James Financial reaffirmed an “outperform” rating on shares of BioNTech in a research note on Tuesday, March 10th. Bank of America reiterated a “buy” rating and set a $128.00 target price on shares of BioNTech in a report on Tuesday, March 10th. Finally, The Goldman Sachs Group reissued a “buy” rating on shares of BioNTech in a research report on Wednesday, March 11th. One equities research analyst has rated the stock with a Strong Buy rating, twelve have issued a Buy rating, four have issued a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average price target of $133.73.

About BioNTech

BioNTech SE (NASDAQ: BNTX) is a Germany-based biotechnology company that develops next-generation immunotherapies and vaccines, with a primary focus on messenger RNA (mRNA) technology. Founded in 2008 and headquartered in Mainz, BioNTech advances a platform approach to design and manufacture therapeutics across oncology, infectious diseases and other high unmet-need areas. The company is publicly traded on the NASDAQ exchange and became widely known for its rapid development and global deployment of an mRNA-based COVID-19 vaccine in collaboration with Pfizer.

BioNTech’s core activities include discovery research, clinical development and manufacturing of mRNA-based medicines, personalized cancer immunotherapies, engineered cell therapies, and antibody- and protein-based therapeutics.